Clinical Trial Update: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer [Phase 3]

View source ↗

Summary

This Clinical Trial Update reports a two-part Phase 3 study of Sofetabart Mipitecan (LY4170156) in platinum-resistant and platinum-sensitive ovarian cancer, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Sofetabart Mipitecan (Mipitecan)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 3 | Status: RECRUITING